'Front and center': Industry leaders call for response to Supreme Court abortion case draft
Biotech industry leaders want the drug development world to stand up and ensure employees have access to abortions after a draft ruling last week revealed the nation’s highest court might overturn a nearly five-decade-old ruling, known by two names: Roe v. Wade.
“We have to make noise, for one thing, which is effective, but also encourage people to take some sort of action,” Paul Hastings told Endpoints News. Last week, the Nkarta CEO and BIO chair called on his fellow biotech companies to help pay for travel expenses for employees in states hindering access to reproductive health.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.